The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis
- 주제(기타) Oncology; Radiology, Nuclear Medicine & Medical Imaging
- 설명문(일반) [Chang, Won Ick; Kang, Hyun-Cheol; Chie, Eui Kyu] Seoul Natl Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Kim, Byoung Hyuck] Seoul Natl Univ, Boramae Med Ctr, Dept Radiat Oncol, Seoul Metropolitan Govt, Seoul, South Korea; [Kim, Kyubo] Ewha Womans Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Lee, Kyung-Hun; Oh, Do-Youn] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Kim, Hongbeom; Kwon, Wooil; Jang, Jin-Young] Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea; [Chie, Eui Kyu] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 ELSEVIER SCIENCE INC
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000183623
- 본문언어 영어
- Published As http://dx.doi.org/10.1016/j.ijrobp.2021.05.012
- PubMed https://pubmed.ncbi.nlm.nih.gov/34029643
초록/요약
Purpose: Despite frequent use in the clinical setting, especially for patients with high-risk factors for relapse, the role of adju-vant treatment has not been clarified in nonhilar extrahepatic bile duct cancer (NH-EHBDC). The goal of this study is to iden-tify the role of adjuvant chemoradiotherapy (CRT) in NH-EHBDC patients after radical surgery. Methods and Materials: Patients with NH-EHBDC who underwent radical surgery from July 2007 to December 2018 were reviewed retrospectively. Univariate and multivariate analyses were conducted to identify prognostic factors for locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Subgroup analyses were performed to further identify the role of adjuvant CRT. Results: Three hundred twenty-eight patients were accrued. At a median follow-up of 37.1 months (range, 1.0-144.2 months), the 3-year LRRFS, DMFS, DFS, and OS were 63.4%, 59.0%, 53.2%, and 67.5%, respectively. In multivariate analysis, adjuvant CRT was an independent prognostic factor for LRRFS, DMFS, DFS, and OS (P < .05). For patients with nodal involvement, pT3 stage, tumor size > >= 5 cm, poorly differentiated tumor, and R1 resection, adjuvant CRT significantly improved DFS (P < .05). Conclusions: In patients with NH-EHBDC, adjuvant CRT significantly improved LRRFS and DFS. For patients with risk fac-tors such as nodal involvement, pT3 stage, poorly differentiated tumor, tumor size >= 5 cm, or R1 resection, adjuvant CRT might contribute to improve treatment outcomes. (C) 2021 Elsevier Inc. All rights reserved.
more